Oral C5 inhibitor - BioCryst Pharmaceuticals
Latest Information Update: 28 Mar 2024
At a glance
- Originator BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders; Myasthenia gravis